{"schema_version":"secwatch.filing_event.v1","accession":"0001816590-26-000021","form_type":"8-K","ticker":"CMPS","cik":"0001816590","company_name":"COMPASS Pathways plc","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.282741+00:00","generated_at":"2026-05-15T09:14:40.452934+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Compass Pathways 2025 net loss $287.9M; COMP360 NDA submission on track for Q4 2026","bullets":["Full-year 2025 net loss $287.9M ($3.08/share), vs $155.1M in 2024; includes $122.6M non-cash loss on warrant liabilities.","Q4 2025 net loss $93.9M ($1.00/share), vs $43.3M in Q4 2024.","COMP360 in TRD: highly statistically significant Phase 3 results; FDA meeting to confirm rolling NDA submission, expected completion in Q4 2026.","Phase 2b/3 trial in PTSD initiated after FDA acceptance of IND.","Cash $149.6M at Dec 31, 2025; $150M Feb financing plus $200M warrant exercise extends cash runway into 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001816590-26-000021","json":"https://secwatch.observer/filing/0001816590-26-000021.json","markdown":"https://secwatch.observer/filing/0001816590-26-000021.md","text":"https://secwatch.observer/filing/0001816590-26-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/0001816590-26-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/cmps-20260324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:14:40.452934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e378eb4ae4791d241f7124f71858a8df6721468f","claim":"COMPASS Pathways plc reported financial results for the year ended December 31, 2025.","evidence_excerpt":"Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported the fourth quarter and full-year 2025 financial results and business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/0001816590-26-000021-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}